Narra J最新文献

{"title":"Beetroot (<i>Beta vulgaris</i>) potential in preventing colorectal cancer using in-silico analysis.","authors":"Adisti Dwijayanti, Norma N Azizah, Linda Erlina, Kusmardi Kusmardi, Sri S Ningsih, Fadilah Fadilah, Najihah M Hashim","doi":"10.52225/narra.v5i2.1578","DOIUrl":"10.52225/narra.v5i2.1578","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide, necessitating the need for an effective therapeutic strategy. <i>Beta vulgaris</i> (beetroot) possesses active compounds that exert anti-cancer properties. The aim of this study was to evaluate the potential of beetroot as a preventative agent against the progression of CRC using differentially expressed gene (DEG) analysis and network pharmacology approaches. The protein-protein interaction network and molecular docking analyses were employed to assess the key interactions of beetroot active compounds with CRC-related target protein. Cytotoxicity of beetroot extract was experimentally evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) assay on the HT29 cell line. The result of this study showed that protein in the cell cycle was significantly enriched in CRC, with <i>cyclin-dependent kinase 4</i> (<i>CDK4</i>) gene as one of the specific genes. Quercetin, galangin, hesperidin, farrerol, and betanin were the most typical compounds of beetroot based on the Comparative Toxicogenomics Database (CTD). Molecular docking studies revealed the strong binding affinity between quercetin (-7.04 kcal/mol) and bentanin (-8.11 kcal/mol) with CDK4. Beetroot demonstrated anticancer properties against the HT29 cell line with IC₅₀ value of 39.03±1.4 µg/mL. In conclusion, the beetroot extract has inhibitory activity against HT29 cell line proliferation, highlighting its potential in preventing the development of CRC through the substantial suppression of gene expression within the cell cycle pathway.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1578"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichen substances from <i>Teloschistes flavicans</i> (Sw.) Norman: Isolation, crystal structure, and evaluation of their antibacterial activities.","authors":"Friardi Ismed, Nurwahidatul Arifa, Mentari Q Nissa, Deddi P Putra, Analia Ic Orue, Jack K Clegg, Isabelle Rouaud, L Dévéhat Françoise","doi":"10.52225/narra.v5i2.1463","DOIUrl":"10.52225/narra.v5i2.1463","url":null,"abstract":"<p><p><i>Teloschistes flavicans</i> (Sw.) Norman is a lichen known as the golden-haired lichen. This lichen has been recognized and used in herbal medicine mixtures as an antimicrobial and bioindicator of air pollution that plays a role in ecological systems. The aim of this study was to explore the potential of its secondary metabolites as antibacterial and anticancer agents, particularly against bacterial pneumonia. Two main compounds (vicacinin and parietin) were isolated with chromatography and identified by spectrometry and single- crystal X-ray diffraction. The crystallographic data of vicanicin are reported for the first time. Chromatography and recrystallization methods were used to obtain both compounds with orange (parietin) and white (vicanicin) crystals. Furthermore, these compounds were evaluated for cytotoxicity on keratinocytes (HaCaT) cells and antibacterial activity against pneumonia pathogens (<i>Klebsiella pneumoniae</i> ATCC 1706, <i>Streptococcus pneumoniae</i> ATCC 49619, <i>Moraxella catarhalis</i> ATCC 25240, and <i>Staphylococcus pyogenes</i> ATCC 19615). The cytotoxic activity of these compounds was moderate at the concentration of 50-100 µM. The antibacterial pneumonia activity was relatively weak compared to chloramphenicol. Between the two compounds, vicanicin showed stronger activity than parietin against all strains. Vicanicin was more active against <i>Klebsiella pneumoniae</i> and <i>Staphylococcus pyogenes</i> with minimum inhibitory concentrations of 156±0.77 µM and 156±0.91 µM, respectively. In this study, comprehensive molecular structures of parietin and vicanicin have been successfully elucidated, and their antibacterial and cytotoxic activities have been provided.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1463"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical cost inflation and its drivers in Indonesian employer-sponsored health insurance for retiree families.","authors":"Cahya E Prastyo, Ascobat Gani","doi":"10.52225/narra.v5i2.2528","DOIUrl":"10.52225/narra.v5i2.2528","url":null,"abstract":"<p><p>Rising life expectancy and changes in disease patterns have led to an increase in retiree medical costs. Understanding these trends is essential for ensuring the financial sustainability of retiree healthcare programs. The aim of this study was to analyze medical cost inflation and its drivers in Indonesia's employer-sponsored retiree health insurance program from 2020 to 2023. A retrospective cohort study using total sampling included 29,695 retirees, analyzing medical records and insurance claims to examine demographic transition, cost analysis and relative risk of cost drivers. The study found that the retiree population is aging, characterized by longer life expectancy and a growing proportion of individuals aged above 71 years. Medical cost inflation among retirees is higher compared to the general population, driven by aging, high-cost diseases, increased healthcare utilization, and rising treatment costs. Cardiovascular diseases, diabetes, and chronic kidney disease are major drivers of high medical costs. Inpatient care is the most significant cost component, with a cost risk 14.39 times higher than clinic visits. Medicine and medical treatment are leading cost contributors in the retired population. The rising cost of retiree healthcare necessitates sustainable financing strategies. The study highlights that medical cost inflation in retirees was higher than in the general population, driven by aging, high-cost diseases, increased utilization, and rising treatment costs. Strengthening preventive care, optimizing primary care, and diversifying funding sources are recommended to ensure long-term financial stability.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e2528"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of clinical prediction score for mortality in tuberculosis patients.","authors":"Pattama Saisudjarit, Surasak Saokaew, Acharaporn Duangjai, Anurak Prasatkhetragarn, Sukrit Kanchanasurakit, Pochamana Phisalprapa","doi":"10.52225/narra.v5i2.1701","DOIUrl":"10.52225/narra.v5i2.1701","url":null,"abstract":"<p><p>Tuberculosis (TB) remains a global and national public health concern, with mortality posing a significant challenge in treatment programs. The aim of this study was to develop a simple risk-scoring system to predict mortality among TB patients and assess its applicability in resource-limited settings. Data from TB patient registries in Phichit Province, Thailand, covering from January 1, 2017, to December 31, 2020, were used. Eligible participants were aged ≥18 years, having completed treatment or death. A risk score was developed and internally validated using logistic regression. Coefficients were used to assign weighted points to predictors and applied to a validation cohort to assess diagnostic performance. The performance was evaluated by generating a receiver operating characteristic (ROC) curve. The study included 2,196 participants, randomly allocated into derivation (n=1,600) and validation (n=596) cohorts. The risk score included Charlson Comorbidity Index scores (1-2 points and ≥3 points) and TB meningitis. It showed an area under ROC curve (AuROC) of 74.34% (95%CI: 70.80-77.88%) with good calibration (Hosmer-Lemeshow χ²: 0.53; <i>p</i>= 0.97). Positive likelihood ratios for low (≤3) and high (≥6) risk were 1.06 (95%CI: 1.03-1.09) and 31.62 (95%CI: 7.23-138.37), respectively. In the validation cohort, AuROC was 79.50% (95%CI: 74.40-84.60%), with 75% and 100% certainty in low- and high-risk groups. In conclusion, this simple risk score, using routine data and two predictors, can predict mortality in TB patients. It may aid clinicians in planning appropriate care strategies. Nevertheless, the tool should undergo external validation before being implemented in clinical practice.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1701"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing dermoscopic pigmented skin lesion classification: A refined approach using the pre-trained Inception-V3 architecture.","authors":"Erwin S Nugroho, Igi Ardiyanto, Hanung A Nugroho","doi":"10.52225/narra.v5i2.1852","DOIUrl":"10.52225/narra.v5i2.1852","url":null,"abstract":"<p><p>Skin cancer is one of the most prevalent cancers worldwide, with early diagnosis being critical for improving survival rates. Dermoscopy, a non-invasive imaging tool, is widely used for identifying pigmented skin lesions. However, its accuracy is heavily dependent on expert interpretation, which introduces variability and limits accessibility in resource-constrained settings. This highlighted the need for automated solutions to enhance diagnostic consistency and aid in early detection. The aim of this study was to develop a refined machine-learning framework for classifying pigmented skin lesions using dermoscopy images. We employed an enhanced Inception-V3 model, a state-of-the-art convolutional neural network, integrated with a simplified soft-attention mechanism, advanced data augmentation techniques, and Bayesian hyperparameter tuning. These innovations improved the model's ability to accurately focus on and identify relevant lesion features, marking a significant advancement in the field. Using the ISIC-2019 dataset, a publicly available resource containing dermoscopy images classified into eight diagnostic categories, we implemented preprocessing steps such as resizing, cleaning, and data balancing. Additionally, ImageNet transfer learning and Bayesian optimization were applied to refine the model. The inclusion of a soft-attention mechanism further enhanced the model's capacity to identify patterns within lesion images. Our model exhibited outstanding performance on the ISIC-2019 dataset, achieving a sensitivity of 98.5%, specificity of 99.62%, precision of 97.42%, accuracy of 97.38%, an F1 score of 97.34%, and an area under the curve (AUC) of 0.99. These metrics underscored the model's superior capability in accurate and reliable classification of pigmented skin lesions, surpassing current benchmarks and demonstrating significant advancements over existing methodologies.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1852"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryotherapy on exfoliative cytological changes for oral mucositis in cancer patients undergoing chemotherapy: A randomized control trial.","authors":"Kadek A Erika, Mulhaeriah Mulhaeriah, Upik A Miskad, Eli Zuraida, Moh S Sangkala, Ika Magfirah, Harun Achmad","doi":"10.52225/narra.v5i2.1644","DOIUrl":"10.52225/narra.v5i2.1644","url":null,"abstract":"<p><p>Oral mucositis is a common complication of chemotherapy that significantly impacts quality of life and may reduce treatment efficacy. While oral cryotherapy has been widely studied as a preventive intervention due to its cost-effectiveness, safety, and ease of use, most research focused on clinical outcomes without incorporating objective cytological assessments of mucosal changes. The aim of this study was to evaluate the effectiveness of oral cryotherapy in managing chemotherapy-induced mucositis using exfoliative cytology to monitor oral mucosal changes. A single-blinded, randomized controlled trial was conducted involving 50 cancer patients undergoing chemotherapy, who were randomly assigned to either the intervention or control group. The control group (n=25) received standard oral hygiene care, while the intervention group (n=25) received oral cryotherapy in addition to routine oral hygiene. A 20-minute oral cryotherapy was administered twice daily after breakfast (09:00 A.M.) and lunch (01:00 P.M.) for 14 days. This study found a significant reduction in mucositis scores was observed in both groups (<i>p</i><0.05). However, post-hoc analysis indicated that mucositis severity declined earlier in the cryotherapy group, whereas improvement in the control group was noted only after 14 days. Serial oral mucosal smears analyzed via exfoliative cytology revealed a reduction in inflammatory cells and the absence of coccus microorganisms by days 7 and 14 in the intervention group. In conclusion, this study demonstrated that oral cryotherapy effectively reduces the severity and duration of mucositis and accelerates recovery in cancer patients undergoing chemotherapy. Oral cryotherapy can be applied as a viable alternative to mitigate the severity of oral mucositis in this patient population.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1644"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotic <i>Lactobacillus</i> sp. as a strategy for modulation of non-comorbid obesity: A systematic meta-analysis and GRADE assessment of randomized controlled trials.","authors":"Juan Ajmn Lele, Karlos B Sihaloho, Dewa Vighneshwara, Derren Dch Rampengan, Chrisandi Y Rizqiansyah, Happy K Permatasari, Nelly Mayulu, Trina E Tallei, Nurpudji A Taslim, Bonglee Kim, Immanuelle Kezia, Fahrul Nurkolis, Rony A Syahputra","doi":"10.52225/narra.v5i2.1562","DOIUrl":"10.52225/narra.v5i2.1562","url":null,"abstract":"<p><p>Given the high prevalence of obesity worldwide, effective therapeutic strategies are crucial to prevent and manage obesity-related health conditions. Existing studies indicate that <i>Lactobacillus</i> sp. showed beneficial effects on body weight and adiposity by modifying the gut microbiota; however, no meta-analysis has been conducted assessing the efficacy of <i>Lactobacillus</i> sp-based probiotics on anthropometric parameters, leptin and adiponectin levels, and gut microbiota composition. The aim of this study was to evaluate the efficacy and safety of probiotic supplementation with <i>Lactobacillus</i> sp. in obese individuals without comorbidities. A systematic search was conducted on November 28, 2024, using five databases: PubMed, Wiley, ScienceDirect, Epistemonikos, and Cochrane. Primary outcomes included changes in body mass index (BMI), body weight, waist and hip circumferences, visceral and subcutaneous fat areas, and total body fat content. Secondary outcomes included alterations in leptin and adiponectin levels, gut microbiota composition, and the incidence of adverse events. A total of 1,058 individuals were included across 12 clinical trials. Significant reductions were observed in BMI (mean difference (MD): -0.40 kg/m²; 95%CI: -0.48-(-0.32), <i>p</i><0.00001), body weight (MD: -1.16 kg; 95%CI: -1.79-(-0.53), <i>p</i>=0.0003), waist circumference (MD: -1.41 cm; 95%CI: -1.75-(-1.08), <i>p</i><0.00001), and hip circumference (MD: -0.85 cm; 95%CI: -1.09-(-0.61), <i>p</i><0.00001) compared to controls. Additionally, compared to control group, significant reductions were observed in visceral and subcutaneous fat mass (MD: -7.35; 95%CI: -9.95-(-4.75); <i>p</i><0.00001) and overall body fat (MD: -1.11; 95%CI: -1.31-(-0.91); <i>p</i><0.00001). Leptin levels significantly decreased (MD: -2.11 μg/mL; 95%CI: -3.59-(-0.64), <i>p</i>=0.005) compared to before <i>Lactobacillus</i> sp. supplementation, while adiponectin levels increased (MD: 0.71 μg/mL; 95%CI: 0.22-1.20, <i>p</i>=0.004) following <i>Lactobacillus</i> sp. supplementation compared to placebo group. No significant adverse events were reported in either the intervention or control groups. In conclusion, <i>Lactobacillus</i> sp. probiotic supplementation may serve as an adjuvant therapy to enhance obesity management in non-comorbid obese individuals.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1562"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine attenuates chemical hypoxia-induced pyroptosis through downregulation of nuclear factor kappa B and caspase-1 in cardiomyocytes.","authors":"Budi Satrijo, Mohammad S Rohman, Aulanni'am Aulanni'am, Hidayat Sujuti, Bayu Lestari","doi":"10.52225/narra.v5i2.2245","DOIUrl":"10.52225/narra.v5i2.2245","url":null,"abstract":"<p><p>Myocardial infarction (MI) is the leading cause of mortality worldwide. During MI, cardiomyocyte necrosis and inflammation are crucial in the post-MI cardiac remodeling process, including pyroptosis. Although colchicine is a well-known anti-inflammatory drug that has been clinically studied in the context of MI, its role in cardiac pyroptosis remains unclear. The aim of this study was to investigate the role of colchicine in pyroptosis in vitro, using CoCl₂-induced H9c2 cells. Prior to the primary experiment, the hypoxic model in H9c2 cells was optimized by evaluating hypoxia-inducible factor-1 alpha (HIF-1α) expression and viability in cells exposed to various concentrations of CoCl₂ at different time intervals. Subsequently, an in vitro hypoxia model was established by treating H9c2 cells with CoCl₂ (600 µM), with or without colchicine (1 µM), for 3 hours. Flow cytometry was used to measure the expression of nuclear factor-kappa beta (NF-κB), interleukin 18 (IL-18), caspase-1, and HIF-1α in pyroptotic cells. Immunofluorescence was used to assess caspase-1 localization and its colocalization with propidium iodide during late-stage pyroptosis. Our data indicated that CoCl₂-induced hypoxia significantly upregulated NF-κB, caspase-1, and IL-18 expression, and increased pyroptotic cell death in H9c2 cells. Colchicine treatment attenuated these effects, leading to a marked reduction in NF-κB, caspase-1, and IL-18 expression in hypoxic cells. Colchicine treatment significantly decreased the number of late pyroptotic cells. The protective effect of colchicine was more pronounced in late hypoxia (24-hour) setting compared to early hypoxia (3-hour). These findings suggest that colchicine attenuates cardiac pyroptosis in hypoxic H9c2 cells, as evidenced by the significant downregulation of key proteins involved in this pathway, including NF-κB, caspase-1, and IL-18. This protective effect appeared to be more effective in late hypoxia.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e2245"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology, molecular docking, and molecular dynamics analyses to explore the molecular mechanism of paclitaxel in atherosclerosis therapy.","authors":"Biomechy Oktomalioputri, Afriwardi Afriwardi, Eryati Darwin, Rauza S Rita","doi":"10.52225/narra.v5i2.2140","DOIUrl":"10.52225/narra.v5i2.2140","url":null,"abstract":"<p><p>Atherosclerosis is a chronic arterial disease and the leading cause of vascular death. Paclitaxel has long been recognized as an anticancer agent, but recent studies have shown that paclitaxel can also potentially reduce the progression of atherosclerosis. The aim of this study was to explore the molecular mechanism of paclitaxel as an atherosclerosis therapy using in silico study. Pharmacokinetic and pharmacodynamic analyses of paclitaxel were conducted using SwissADME, ProTox v3.0, and SCFbio websites. Cytoscape software was used to construct a network of protein-protein interactions, and the key proteins involved in paclitaxel-related atherosclerosis were identified, including AKT serine/threonine kinase 1 (AKT1), Jun N-terminal kinase (JNK), and Endothelin 1 (ET1). These key proteins were then subjected to molecular docking and molecular dynamic simulation using MOE and Yasara applications. Pharmacokinetic and pharmacodynamic analyses revealed that paclitaxel has good distribution, metabolism, and excretion properties. However, paclitaxel has shortcomings in absorption, toxicity, and water solubility. According to the results of molecular docking, paclitaxel showed consistent results as the most potential inhibitor of AKT1 (-9.59 kcal/mol), ET1 (-9.16 kcal/mol), JNK (-8.72 kcal/mol) when compared to the control ligands. Molecular dynamics simulations also confirmed the interaction stability between paclitaxel with AKT1, ET1, and JNK, with paclitaxel-AKT1 demonstrating the highest conformational stability (Carbon-α Root Mean Square Deviation <3.0 Å). Even though our in-silico results are promising, more experimental studies are required to confirm the efficacy of paclitaxel as an atherosclerosis therapy.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e2140"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of vitamin D supplementation on post-stroke rehabilitation outcomes: A systematic review and meta-analysis.","authors":"Etisa A Murbawani, Dodik T Pramukarso, Siti F Muis, Dwi Pudjonarko, Hertanto W Subagio, Kevin C Tjandra, Danendra Rp Respati, Laksmana Ak Nugraha, Ghifarie A Ramadhany, Stephano Pranoto","doi":"10.52225/narra.v5i2.1848","DOIUrl":"10.52225/narra.v5i2.1848","url":null,"abstract":"<p><p>Each year, there are approximately 12.2 million new stroke cases and 6.5 million stroke-related deaths, with low- and middle-income countries shouldering a disproportionately high financial burden. Studies have associated vitamin D deficiency with arteriosclerosis, left ventricular hypertrophy, and vascular dysfunction, contributing to an elevated risk of stroke. The aim of this study was to evaluate how vitamin D supplementation affects post-stroke outcomes. A comprehensive literature search was performed across PubMed, Scopus, the Cochrane Library, ScienceDirect, Springer Link, ProQuest, and Epistemonikos from April to May 2024. This study focused on comparing the efficacy of vitamin D supplementation versus no supplementation in stroke patients of all ages. Outcome measures included the Functional Ambulation Classification (FAC), Brunnstrom Recovery Stage (BRS), Modified Rankin Scale (mRS), and National Institutes of Health Stroke Scale (NIHSS). Case reports, reviews, and research on other cardiovascular or metabolic issues were excluded. Five authors extracted data and analyzed bias separately using the Risk of Bias Version 2 (RoB V2) algorithms. The results of continuous variables were pooled into the mean difference (MD) along with 95% confidence intervals (CI) using random-effect models. Review Manager 5.4 was used to evaluate the data. Out of the 1,152,449 papers evaluated, six met the inclusion criteria, with a sample size ranging from 42 to 123 patients. Vitamin D supplementation was found to yield better outcomes after stroke. BRS in lower extremities showed better results (MD: 0.59 (95%CI: 0.27-0.91)) and NIHSS improved with an MD of -1.47 (95%CI: -2.03-(-0.90)). Furthermore, there was also an improvement in mRS, with an MD of -0.91 (95%CI: -1.25-(-0.56)). In conclusion, vitamin D improved post-stroke outcomes, which supported its supplementation as a part of stroke rehabilitation.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"5 2","pages":"e1848"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}